Hyderabad-based pharma penny stock under Rs 50: Company is set to commence R&D operations on July 28, 2025

Today, shares of Sigachi Industries Ltd surged 0.3 per cent to Rs 40.08 per share from its previous closing of Rs 39.97 per share. The company has a market cap of over Rs 1,500 crore and has delivered good profit growth of 28 per cent CAGR over the last 5 years. From Rs 34.51 per share (52-week low) to Rs 40.08 per share, the stock is up by 16.14 per cent.

Sigachi Industries Limited, a prominent Indian player in pharmaceutical excipients, APIs, and specialty ingredients, is slated to inaugurate its new Research & Development (R&D) Center in Hyderabad on July 28, 2025. This strategic move aims to bolster the company's scientific and technical prowess, with a primary focus on developing a high-value pipeline of Active Pharmaceutical Ingredients (APIs) for global markets. The R&D Center is designed to oversee the entire API development process, from initial lab-scale innovation through to commercialisation and global regulatory filings.

The new R&D facility will house a dedicated team of 32-35 skilled R&D scientists committed to expediting product development for regulated markets. Sigachi's API pipeline will target both commercialisation and CEP (Certificate of Suitability) filings across key therapeutic segments, with specific molecules already identified for accelerated development. Emphasising Quality-by-Design (QbD) and robust regulatory preparedness, the R&D Center is poised to be a cornerstone of Sigachi's pharmaceutical innovation strategy, enhancing its competitive edge in the global market.

The following molecules have been identified for accelerated development:

Commenting on this development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited stated “By investing in end-to-end R&D capabilities and consolidating API development and analytical functions under one roof, we are not just strengthening our backward integration — we are laying the foundation for Sigachi to emerge as a high-quality, globally competitive supplier in regulated pharmaceutical markets.”

About the Company

Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialise in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilising advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.

The company announced positive Quarterly Results (Q4FY25) and annual results (FY25). According to quarterly results, revenue increased by 23 per cent to Rs 128.21 crore, EBITDA increased by 30 per cent to Rs 30.75 crore and net profit increased by 7 per cent to Rs 16.17 crore in Q4FY25 compared to Q4FY24. In its annual results, revenue increased by 22 per cent to Rs 488.24 crore, EBITDA increased by 36 per cent to Rs 120.50 crore and consolidated PAT increased by 22 per cent to Rs 70.46 crore in FY25 compared to FY24.

Disclaimer: The article is for informational purposes only and not investment advice.